UCB S.A. - Product Pipeline Review - 2016

Published: Apr, 2016 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

UCB S.A. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2016', provides an overview of the UCB S.A.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
- The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses UCB S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features UCB S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for UCB S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding UCB S.A.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

Table of Contents

Table of Content 2
List of Tables 5
List of Figures 5
UCB S.A. Snapshot 6
UCB S.A. Overview 6
Key Information 6
Key Facts 6
UCB S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
UCB S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
UCB S.A. - Pipeline Products Glance 16
UCB S.A. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
UCB S.A. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
UCB S.A. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
UCB S.A. - Drug Profiles 22
brivaracetam 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
certolizumab pegol 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lacosamide 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
levetiracetam 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotigotine ER 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
bimekizumab 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
seletalisib 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
UCB-0942 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
UCB-7665 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dapirolizumab pegol 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
UCB-4144 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
UCB-6673 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Antibodies for Cancer, Immunology and Inflammation 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antibody to Inhibit Transglutaminase 2 for Fibrosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
UCB S.A. - Pipeline Analysis 59
UCB S.A. - Pipeline Products by Target 59
UCB S.A. - Pipeline Products by Route of Administration 61
UCB S.A. - Pipeline Products by Molecule Type 62
UCB S.A. - Pipeline Products by Mechanism of Action 63
UCB S.A. - Recent Pipeline Updates 65
UCB S.A. - Dormant Projects 81
UCB S.A. - Discontinued Pipeline Products 82
Discontinued Pipeline Product Profiles 82
CDP-323 82
CDP-435 82
CDP-484 82
lacosamide 82
seletracetam 83
UCB-2892 83
UCB S.A. - Company Statement 84
UCB S.A. - Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

UCB S.A., Key Information 6
UCB S.A., Key Facts 6
UCB S.A. - Pipeline by Indication, 2016 8
UCB S.A. - Pipeline by Stage of Development, 2016 10
UCB S.A. - Monotherapy Products in Pipeline, 2016 11
UCB S.A. - Partnered Products in Pipeline, 2016 12
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13
UCB S.A. - Out-Licensed Products in Pipeline, 2016 14
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
UCB S.A. - Pre-Registration, 2016 16
UCB S.A. - Phase III, 2016 17
UCB S.A. - Phase II, 2016 18
UCB S.A. - Phase I, 2016 19
UCB S.A. - Preclinical, 2016 20
UCB S.A. - Discovery, 2016 21
UCB S.A. - Pipeline by Target, 2016 59
UCB S.A. - Pipeline by Route of Administration, 2016 61
UCB S.A. - Pipeline by Molecule Type, 2016 62
UCB S.A. - Pipeline Products by Mechanism of Action, 2016 64
UCB S.A. - Recent Pipeline Updates, 2016 65
UCB S.A. - Dormant Developmental Projects,2016 81
UCB S.A. - Discontinued Pipeline Products, 2016 82
UCB S.A., Subsidiaries 86